Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 626-633

  Koh, Kwang Kon ^a   Horne III, McDonald K ^b   Cannon III, Richard O ^b,c  

^a Gachon University College of Medicine   (South Korea)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; ESTROGEN; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RALOXIFENE; TAMOXIFEN;

ATHEROSCLEROSIS; BLOOD CLOTTING; BREAST CANCER; CONFERENCE PAPER; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS;

EID: 0032699150     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615889     Document Type: Conference Paper

References (58)

1. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
2. Stampfer MJ, Coditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
4. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
5. Meade TW, Imerson JD, Haines AP, Stirling Y, Thompson SG. Menopausal status and haemostatic variables. Lancet. 1983;1:22-24.
6. Balleisen L, Bailey J, Epping P-H, Shulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using, and menopause. Thromb Haemost. 1985;54:475-479.
7. Scarabin P-Y, Bonithon-Knopp C, Bara L, Malmejac A, Guize L, Samama M. Factor VII activation and menopausal status. Thromb Res. 1990;57:227-234.
8. Bonithon-Kopp C, Scarabin P-Y, Darne B, Malmejac A, Guize L. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int J Epidemiol. 1990;19:42-48.
9. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effect of the menopause. Br J Haematol. 1990;74:77-81.
10. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91:191-205.
11. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1995;273:199-208.
12. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Weltry FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952-1958.
13. Scarabin P-Y, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost. 1993;70:584-587.
14. Pinto S, Rostagno C, Coppo M, Paniccia R, Prisco D, Bruni V, Rosati D, Abbate R. No signs of increased thrombin generation in menopause. Thromb Res. 1990;58:645-651.
15. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258:1183-1186.
16. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma; risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
17. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
18. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni MB, Donati M, Cardillo M, Catalono M, Gabrielli L, Lombardi G, Specchia G, Tarazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. Arterioscler Thromb Vasc Biol. 1993;12:1412-1417.
19. Daly E, Vessey MP, Hawkins MM, Carson, JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-980.
20. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet. 1996;348:981-983.
21. Gutthatm SP, Garcia Rodriguez LA, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997;314:796-800.
22. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983-987.
23. Hulley S, Grady D, Bush T, Furberg C, Herrington DM, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
24. The Coronary Drug Project Research Group. The Coronary Drug Project: initial findings leading to modifications of its research protocol. JAMA. 1970;214:1303-1313.
25. Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special references to oral contraceptive practice. BMJ. 1975;2:241-245.
26. Mammen EF. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol. 1982;142:781-790.
27. Caine YG, Bauer KA, Barzegar S, Ten Cate H, Sacks FM, Walsh BM, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992;68:392-395.
28. Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost. 1994;71:420-423.
29. Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17:3071-3078.
30. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
31. Shahar E, Folsom AR, Salomaa VV, Stinson VL, McGovern PG, Shimakawa T, Chambless LE, Wu KK, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Circulation. 1996;93:1970-1975.
32. Sporrong T, Mattson L-A, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol. 1990;97:939-944.
33. Gilabert J, Estelles A, Cano A, Espana F, Barrachina R, Grancha S, Aznar J, Tortajada M. The effect of estrogen replacement therapy with or without progestin on the fibrinolytic system and caogulation inhibitors in postmenopausal status. Am J Obstet Gynecol. 1995;173:1849-1854.
34. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO III. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336:683-690.
35. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem. 1991;266:2459-2465.
36. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, Yasue M. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res. 1993;73:335-343.
37. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA. 1991;88:9959-9963.
38. Kooistra T. The use of cultured human endothelial cells and hepatocytes as an in vitro model system to study modulation of endogenous fibrinolysis. Fibrinolysis. 1990;4(Suppl. 2):33-39.
39. Quax PHA, van den Hoogen CM, Verheijen JH, Padro T, Zeheb R, Gelehrter TD, van Berkel TJ, Kuiper J, Emeis JJ. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem. 1990;265:15560-15563.
40. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest. 1991;88:1346-1353.
41. Beebe DP, Aronson DL. Turnover of human tissue plasminogen activator (t-PA) in rabbits. Thromb Res. 1986;43:663-674.
42. Korninger C, Stassen J-M, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemost. 1981;46:658-661.
43. 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA. 1992;89:7427-7431.
44. 2-macroglobulin receptor. Proc Natl Acad Sci USA. 1992;89:7422-7426.
45. 2-macroglobulin receptor/LDL receptor-related protein binds urokinase-plasminogen activator inhibitor type-1 complex. J Biol Chem. 1992;267:14543-14546.
46. Windler E, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver: a binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins containing apoproteins B and E. J Biol Chem. 1980;225:10464-10471.
47. Koh KK, Home MK III, Csako G, Waclawiw MA, Cannon RO III. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. Am J Cardiol. In press.
48. Chandler WL, Trimble SL, Lou W-C, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood. 1990;76:930-937.
49. Sato M, Rippy MK, Bryant HU. Ralxoifene, tamoxifen, nafoxidine, and or effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996;10:905-912.
50. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol. 1996;10:1167-1177.
51. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-1618.
52. Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO III. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol. 1995;76:1072-1073.
53. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman AI, Farrar W, Evans J, Lickley HL, Ketner M, and other National Surgical Adjuvant Breast and Bowel Project Investigators. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-484.
54. Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Paker J, for the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996;14:2731-2737.
55. Fisher B, Constatino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, and other National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel P-I Study. J Natl Cancer Inst. 1998;90:1371-1388.
56. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metaboliites of 17β-estradiol and raloxifene. Science. 1996;273:1222-1225.
57. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst. 1996;88:123-125.
58. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1451.